Literature DB >> 18271415

[Place of laparoscopic cysts decortication (LCD) in the treatment of autosomal dominant polycystic kidney disease (AD PKD)].

Mieczyslaw Fryczkowski1, Jacek Huk, Aleksandra Sitko-Saucha, Andrzej Kupilas.   

Abstract

INTRODUCTION: Decortication of many cysts in patients with autosomal dominant policystic kidney disease (AD PKD) allows to reduce renal mass, decreases hydrostatic pressure in cysts; moreover it diminishes pain.
METHODS: Between the years 2000-2005, 15 patients underwent laparoscopic cyst decortication (LCD) inculuding 5 (33.3%) men and 10 (66.7%) women. Patients age ranged between 41-73 years (mean 54 y.). Two patients underwent extraperitoneal and 13 transperitoneal LCD. In 2 patients were performed bilateral and in others unilateral decortication. LCD was done in 6 patients on the left side and in 7 on the right side. In all patients except three only 3 ports were used during these operations. Preoperative and postoperative diagnos was based on physical, laboratory, sonographic and computer tomografy (CT) examinations. Renal function was estimated by GFR and renal dynamic Tc99 scyntigraphy. Pain intensity was estimated in visual (VAS) 10 degree score. Follow-up after LCD was 9 to 77 months (mean 36 months).
RESULTS: The mean operative time and the mean hospitalization time were respectively: 197 minutes and 5,4 days. The mean convalescence time was 10.5 days. The mean number of operated cysts was 43,5 per one patient. Pain was relieved in all (100%) patients into 6 months after LCD but has returned in 20% patients after 12 months and in 27% patients after 24 months. Hypertension regressed in 4 patients among 6 (40.0%) with high blood pressure before operation, but haematuria regressed in all patients among 5 (33.3%) with this symptom before LCD. The mean renal function (GFR) increase was observed about 10%, but blood purification in scitiscanning about 4.9% in all patients.
CONCLUSIONS: (1) Laparoscopic cyst decortication (LCD) in patients with symptomatic AD PKD is safe, effective and repeatable alternative to non-radical open surgery. (2) LCD stabilizes renal function which together with improved renal perfusion and renal decontamination decreases number of severe, life-threatening complications.

Entities:  

Mesh:

Year:  2007        PMID: 18271415     DOI: 10.1016/s1166-7087(07)78570-6

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  5 in total

1.  Long-term functional results of aspiration and sclerotherapy with ethanol in patients with autosomal dominant polycystic kidney disease: a non-randomized pilot clinical study.

Authors:  Eyüp Veli Küçük; Ahmet Tahra; Ahmet Bindayi; Ferhat Yakup Suçeken; Fikret Fatih Önol; Uğur Boylu
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

2.  Hyperbaric oxygen therapy in a patient with autosomal dominant polycystic kidney disease with a perinephritic abscess.

Authors:  Jorge Vega; Helmuth Goecke; Francisco Manriquez; Carlos Escobar; Max Escobar; Christian Videla; Mario Santamarina; Carlos Echeverria; Francisco Javier Guarda
Journal:  Clin Exp Nephrol       Date:  2010-10-01       Impact factor: 2.801

Review 3.  Surgical cyst decortication in autosomal dominant polycystic kidney disease.

Authors:  Melissa Millar; Youssef S Tanagho; Mohammed Haseebuddin; Ralph V Clayman; Sam B Bhayani; R Sherburne Figenshau
Journal:  J Endourol       Date:  2013-02-05       Impact factor: 2.942

Review 4.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

5.  Should kidney volume be used as an indicator of surgical occasion for patients with autosomal dominant polycystic kidney disease?

Authors:  Jiang Yu; Bin Li; Yu-Zhu Xiang; Tai-Guo Qi; Xun-Bo Jin; Hui Xiong
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.